In recent months, the Asian markets have experienced a mix of volatility and resilience, with geopolitical tensions and energy price fluctuations impacting investor sentiment. Amid these conditions, growth companies with strong insider ownership can offer a valuable perspective on potential stability and confidence within the market.
| Name | Insider Ownership | Earnings Growth |
| Zhejiang Taotao Vehicles (SZSE:301345) | 27.9% | 31.5% |
| Seojin SystemLtd (KOSDAQ:A178320) | 18% | 110.8% |
| Meiko Electronics (TSE:6787) | 19.2% | 30.1% |
| L&C BIOLTD (KOSDAQ:A290650) | 24% | 148.5% |
| HUMAN MADE (TSE:456A) | 23.9% | 29.2% |
| Guangzhou Tinci Materials Technology (SZSE:002709) | 38.4% | 28.3% |
| Great Microwave Technology (SHSE:688270) | 29.5% | 85.5% |
| Gpixel Changchun Microelectronics (SEHK:3277) | 18.2% | 34.2% |
| Gold Circuit Electronics (TWSE:2368) | 29.8% | 42.6% |
| Fulin Precision (SZSE:300432) | 11.2% | 60.7% |
We'll examine a selection from our screener results.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Laopu Gold Co., Ltd. designs, manufactures, and sells jewelry products in Mainland China, Hong Kong, and Macau with a market cap of approximately HK$65.43 billion.
Operations: The company's revenue is primarily generated from its Jewelry & Watches segment, amounting to CN¥27.30 billion.
Insider Ownership: 19.2%
Earnings Growth Forecast: 16.4% p.a.
Laopu Gold is experiencing robust growth, with revenue expected to grow 13.7% annually, surpassing the Hong Kong market's average of 8.7%. Its earnings are forecast to increase by 16.4% per year, outpacing the market's 11.8%. Despite trading at a significant discount to its estimated fair value, Laopu Gold has no recent insider trading activity and offers a high dividend yield that isn't well covered by free cash flows. Recent corporate guidance indicates substantial revenue growth driven by brand expansion and product optimization.
Simply Wall St Growth Rating: ★★★★★☆
Overview: CanSino Biologics Inc. is a company based in the People's Republic of China that focuses on developing, manufacturing, and commercializing vaccines, with a market cap of HK$12.84 billion.
Operations: The company's revenue primarily comes from the research and development of vaccine products for human use, totaling CN¥1.12 billion.
Insider Ownership: 31.1%
Earnings Growth Forecast: 57.2% p.a.
CanSino Biologics is positioned for significant growth, with its revenue projected to increase by 23.1% annually, outpacing the Hong Kong market. The company has recently made strides in expanding its vaccine portfolio, including the Td5cp Adolescent and Adult booster vaccine addressing a gap in China's market. Despite high share price volatility and no recent insider trading activity, CanSino trades below fair value estimates and is expected to achieve profitability within three years.
Simply Wall St Growth Rating: ★★★★★★
Overview: Northsand, Inc. offers IT consulting, business consulting, and new business launch services in Japan with a market cap of ¥140.35 billion.
Operations: The company's revenue primarily comes from its Software & Programming segment, generating ¥9.19 billion.
Insider Ownership: 22%
Earnings Growth Forecast: 34.1% p.a.
Northsand is poised for robust growth, with earnings projected to rise 34.09% annually, surpassing the JP market's growth rate. Revenue is expected to grow by 28.5% per year, significantly outpacing the market average. Despite recent share price volatility and no substantial insider trading activity in the past three months, Northsand's high insider ownership aligns with its strategic move towards listing on the Tokyo Stock Exchange's Prime Market following its inclusion in the S&P Global BMI Index.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com